Topic: Alcohol/Drugs/Tobacco
Target Population: Adults
Sector: Community-Based
This program is for adults who are addicted to stimulants such as methamphetamines and cocaine.
The Matrix Model®, an intensive outpatient program, is designed to engage participants in treatment and help them achieve abstinence from stimulant use.
Results of several evaluations of the Matrix Model indicate mixed short-term findings. There is some evidence that program participants were more likely than members of a comparison group to complete treatment and to avoid methamphetamine and opiate use while in treatment. Program participants also experienced improvements in quality of life, self-efficacy, distress tolerance, mindfulness, self-control, and emotion regulation, and decreases in depression, anxiety, stress, and temptation and cravings for drugs from pre- to posttest, compared to a control group. However, these findings were inconsistent. Furthermore, there were no differences between members of the treatment and comparison groups 6 and 12 months after beginning the program, which indicates a lack of sustained effects. Results from one study among methamphetamine-dependent patients and caregivers indicated significant decreases in depression and anxiety and significant increases in quality of life at 6 months following the intervention; however, there were no measures of drug use in this study.
The Matrix Model is an intensive outpatient program, and family involvement is highly encouraged. The program covers key areas including individual and group therapy, early recovery, relapse prevention, family education, social support, and drug-screening strategies. In addition, participation in a Twelve Step program is encouraged throughout. The program includes the following eight principles that guide treatment:
The Matrix Model is based on an integrated therapeutic model. This program draws elements from multiple approaches, such as cognitive behavioral therapy (CBT), motivational enhancement, couples and family therapy, individual supportive/expressive psychotherapy, group therapy, contingency management twelve-step facilitation, and social support.
The Matrix Model has been used in the treatment of more than 6,000 cocaine and 2,500 methamphetamine addicts.
This program is facilitated by therapists who have experience in CBT, motivational interviewing, and the physiology of addiction. Optional on-site and online training options are available. A 2-day training for facilitators costs $1,200 per person for both days. For more information, please visit https://www.clarematrixtraininginstitute.org/ or use details in the Contact section.
Considerations for implementing this program include recruiting suitable therapists and ensuring they complete training, obtaining buy-in from participants, and finding time and space to deliver program sessions.
The Clearinghouse can help address these considerations. Please call 1-877-382-9185 or email Clearinghouse@psu.edu
If you are interested in implementing the Matrix Model, the Clearinghouse is interested in helping you!
Please call 1-877-382-9185 or email Clearinghouse@psu.edu
Participants are involved in treatment 7 days a week. Formal treatment sessions (e.g., individual or group therapy) are held three times per week for 16 weeks. During the other days of the week, participants attend informal treatments, such as twelve-step meetings. The program may be extended up to 12 months, if needed.
The basic Matrix Model package costs $745. Please visit https://www.hazelden.org/store/item/311126 for more information. The package may also be purchased with the addition of several DVDs and costs $1,595. Please visit https://www.hazelden.org/store/item/538254 to learn more.
To move the Matrix Model to the Unclear 0 (mixed) category on the Clearinghouse Continuum of Evidence, at least one evaluation should be performed demonstrating positive effects lasting at least one year from the beginning of the program or at least six months from program completion.
The Clearinghouse can help you develop an evaluation plan to ensure the program components are meeting your goals. Please call 1-877-382-9185 or email Clearinghouse@psu.edu
Contact the Clearinghouse with any questions regarding this program.
Phone: 1-877-382-9185 Email: Clearinghouse@psu.edu
You may also contact Hazelden Publishing by mail P.O. Box 176, Center City, MN 55012-0176, phone 1-800-328-9000, or visit https://www.hazelden.org/store/item/311126 or https://www.hazelden.org/store/item/538254? or contact CLARE/MATRIX by mail 909 Pico Boulevard, Santa Monica, CA 90405, phone 1-310-314-6200, or visit https://www.clarematrix.org/training/the-matrix-model/.
Amiri, Z., Mirzaee, B., & Sabet, M. (2016). Evaluating the efficacy of regulated 12-session matrix model in reducing susceptibility in methamphetamine-dependent individuals. International Journal of Medical Research & Health Sciences, 5(2), 77-85.
Basereh, S., Safarzadeh, S., & Hooman, F. (2022). Comparison of the effect of two interventions of group dialectical behavior therapy and structured matrix treatment on pathological narcissism and craving for drugs among drug abusers. Journal of Multidisciplinary Care, 11(2), 77-82.
Basereh, S., Safarzadeh, S., & Hooman, F. (2022). The effectiveness of group dialectical behavior therapy and structured matrix treatment on quit addiction self-efficacy, distress tolerance, and mindfulness in individuals with stimulant drug abuse. Journal of Health Reports and Technology, 8(4), e127427.
Farhad, H., Abolghasemi, S., & Hamzehpoor, T. (2022). Effectiveness of matrix treatment on depression and temptation in consumption in amphetamine dependent individuals. Iranian Evolutionary Educational Psychology Journal, 4(4), 76-83.
Ghasemnezhad, S., Ghasemian, D., Gheytarani, B., Ghorbani, F., & Ghahari, S. (2016). The effectiveness of matrix treatment to relapse prevention and increase self-efficacy in people withdrawing methamphetamine. International Journal of Medical Research & Health Sciences, 5(8), 340-345.
Hoe, H. D., Tran, K., Van Hai, N., Trang, P. T. H., & Lien, N. T. (2021). Assessment of the effectiveness of matrix model among methadone patients using ATS in Ho Chi Minh City, Vietnam. Journal La Medihealtico, 2(5), 26-34.
Masaeli, N., Zarkob, H., Kheirabadi, G., Soleimani, N., & Amini, M. (2018). The effect of matrix model on depression, anxiety, and quality of life in methamphetamine users and their caregivers. Addictive Disorders & their Treatment, 17(4), 186-190. https://doi.org/10.1097/ADT.0000000000000136
Rawson, R. A., Marinelli-Casey, P., Anglin, M. D., Dickow, A., Frazier, Y., Gallagher, C., ... Methamphetamine Treatment Project Corporate Authors. (2004). A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction, 99(6), 708-717. https://doi.org/10.1111/j.1360-0443.2004.00707.x
Rawson, R. A., Shoptaw, S. J., Obert, J. L., McCann, M. J., Hasson, A. L., Marinelli-Casey, P. J., ... Ling, W. (1995). An intensive outpatient approach for cocaine abuse treatment: The matrix model. Journal of Substance Abuse Treatment, 12(2), 117-127. https://doi.org/10.1016/0740-5472(94)00080-B
Sami, S., Effatpanah, M., Moradi, A., & Massah, O. (2017). Matrix Model as an intensive rehabilitation in three methadone services in Iran. Iranian Rehabilitation Journal, 15(3), 293-298.
Zanjani, F. A., Jani, H. T., & Amiri, M. (2020). The effectiveness of integrated matrix therapy on self-control and emotional regulation in methamphetamine abusers. Journal of Fundamentals of Mental Health, 22(1).
Ahmadkhaniha, H., Ebdam, A., Soraya, S., Naserbakht, M., & Khajeh-Azad, M. A. (2024). Does topiramate add-on enhance the response to the MATRIX program in individuals with methamphetamine use disorder? A double-blinded randomized placebo-controlled trial. Journal of Iranian Medical Council, 7(4), 757-768.
Alammehrjerdi, Z., Ezard, N., & Dolan, K. (2018). Methamphetamine dependence in methadone treatment services in Iran: The first literature review of a new health concern. Asian Journal of Psychiatry, 31, 49-55. https://doi.org/10.1016/j.ajp.2018.01.001
Alammehrjerdi, Z., Mokri, A., & Dolan, K. (2015). Methamphetamine use and treatment in Iran: A systematic review from the most populated Persian Gulf country. Asian Journal of Psychiatry, 16, 17-25. https://doi.org/10.1016/j.ajp.2015.05.036
Aryan, N., Banafshe, H. R., Farnia, V., Shakeri, J., Alikhani, M., Rahimi, H., … Omidi, A. (2020). The therapeutic effects of methylphenidate and matrix-methylphenidate on addiction severity, craving, relapse and mental health in the methamphetamine use disorder. Substance Abuse Treatment, Prevention and Policy, 15(1), 1-72. https://doi.org/10.1186/s13011-020-00317-y
AshaRani, P., Hombali, A., Seow, E., Ong, W. J., Tan, J. H., & Subramaniam, M. (2020). Non-pharmacological interventions for methamphetamine use disorder: A systematic review. Drug and Alcohol Dependence, 212, 108060. https://doi.org/10.1016/j.drugalcdep.2020.108060
Azadbakht, A., Salehi, M., Maracy, M. R., & Banafshe, H. R. (2022). The effects of oxytocin on craving, mental health parameters, and stress hormones in methamphetamine-dependent patients undergoing matrix treatment model: A randomized, double-blind clinical trial. European Addiction Research, 28(5), 340-349. https://doi.org/10.1159/000525443
Fayaz Feyzi , Y., Vahed, N., Sadeghamal Nikraftar, N., & Arezoomandan, R. (2022). Synergistic effect of combined transcranial direct current stimulation and matrix model on the reduction of methamphetamine craving and improvement of cognitive functioning: A randomized sham-controlled study. The American Journal of Drug and Alcohol Abuse, 48(3), 311-320. https://doi.org/10.1080/00952990.2021.2015771
Gouse, H., Magidson, J. F., Burnhams, W., Remmert, J. E., Myers, B., Joska, J. A., & Carrico, A. W. (2016). Implementation of cognitive-behavioral substance abuse treatment in Sub-Saharan Africa: Treatment engagement and abstinence at treatment exit. PloS One, 11(1), e0147900. https://doi.org/10.1371/journal.pone.0147900
Huber, A., Ling, W., Shoptaw, S., Gulati, V., Brethen, P., & Rawson, R. (1997). Integrating treatments for methamphetamine abuse: A psychosocial perspective. Journal of Addictive Diseases, 16(4), 41-50. https://doi.org/10.1300/J069v16n04_04
Kaviyani, A. R., Javid, H., Baghooli, H., & Barzegar, M. (2021). Comparison of the effectiveness of motivational interviewing and matrix treatment with Cognitive-Behavioral Approach on depression and quality of life in marijuana users. Quarterly Journal of Psychological Methods and Models Fall, 12(45).
Khuancharee, K., Buaphana, S., & Suwanchatchai, C. (2025). Relapse and depression in rural methamphetamine use disorder: Effects of matrix model treatment in a community setting. International Journal of Mental Health and Addiction, https://doi.org/10.1007/s11469-025-01493-3
Magidson, J. F., Gouse, H., Burnhams, W., Wu, C. Y. Y., Myers, B., Joska, J. A., & Carrico, A. W. (2017). Beyond methamphetamine: Documenting the implementation of the matrix model of substance use treatment for opioid users in a South African setting. Addictive Behaviors, 66, 132-137. https://doi.org/10.1016/j.addbeh.2016.11.014
Nasr, V. A., Salehi, M., & Kheirabadi, G. (2022). The Effect of Perphenazine Add-On Therapy to Matrix Intervention on Control of Craving and Relapse in Methamphetamine Users: A Randomized Controlled Trial. International Journal of High Risk Behaviors and Addiction, 11(2).
Rawson, R. A., Obert, J., McCann, M. J., & Ling, W. (1992). Psychological approaches for the treatment of cocaine dependence-A neurobehavioral approach. Journal of Addictive Diseases, 11(2), 97-119.
Wolitzky-Taylor, K., Sewart, A., Karno, M., Ries, R., & Stimson, J. (2022). Development and initial pilot testing of a fully integrated treatment for comorbid social anxiety disorder and alcohol use disorder in a community-based SUD clinic setting. Behaviour Research and Therapy, 148, 103999. https://doi.org/10.1016/j.brat.2021.103999
